Neurogenic Bladder: Selected Treatments — CPB 0852 | AETNA Coverage Update

Aetna modified CPB 0852 for neurogenic bladder treatments, effective January 5, 2026. Here's what billing teams need to know — and what to stop billing immediately.

Aetna, a CVS Health company, updated its neurogenic bladder coverage policy under CPB 0852 in the Aetna system. The revision expands the experimental and investigational list to 19 named interventions — including AI-based outcome prediction tools, cortical theta burst stimulation, and peripheral neuromodulation — while keeping surgical options CPT 51960 and CPT 50825 as the primary covered procedures. If your practice bills for sacral nerve stimulation, tibial nerve stimulation, or TENS under ICD-10 codes like N31.x or N32.81, this update directly threatens your reimbursement.

Quick-Reference Table

Aetna Neurogenic Bladder Coverage Criteria and Medical Necessity Requirements 2026

The Aetna neurogenic bladder coverage policy under CPB 0852 is narrow by design. Aetna considers only two surgical interventions medically necessary: enterocystoplasty (augmentation cystoplasty), billed as CPT 51960, and urinary diversion surgery, billed as CPT 50825.

To meet medical necessity for either procedure, the patient must have tried and failed conservative treatments first. Conservative treatment means pharmacotherapy — specifically anticholinergic medications — and urinary catheters. If those treatments haven't been tried or documented as contraindicated, your claim for CPT 51960 or CPT 50825 will not hold up to review.

This is a step-therapy requirement, and documentation is everything. Your chart notes need to show what was tried, for how long, and why it failed or couldn't be used. Without that trail, Aetna has grounds to deny on medical necessity — and they will use it.

The source policy is silent on prior authorization requirements within CPB 0852 itself. Verify directly with Aetna before scheduling CPT 51960 or CPT 50825. Don't assume silence means prior auth isn't required.

Reimbursement for these procedures depends entirely on documented failure of conservative care. A clean claim without that documentation is a denial waiting to happen.

Aetna Neurogenic Bladder Exclusions and Non-Covered Indications

This is where the January 5, 2026 update hits hardest. Aetna expanded its experimental and investigational list to 19 distinct interventions. That's not a minor tweak — it's a clear statement that Aetna views most neurogenic bladder treatments outside surgery as lacking clinical evidence.

Here's what Aetna explicitly classifies as experimental, investigational, or unproven for neurogenic bladder:

The sacral nerve stimulation exclusion deserves special attention. Sacral neuromodulation is widely used in urology for overactive bladder, and many teams assume it carries blanket coverage. Under this coverage policy, Aetna draws a hard line: for the neurogenic bladder indication specifically, sacral nerve stimulation is not covered. If your documentation links the diagnosis to neurogenic etiology — ICD-10 codes N31.0 through N31.9 — you're in experimental territory under CPB 0852.

The AI-based outcome prediction exclusion is newer and worth flagging separately. CPT codes 0889T through 0892T cover MRI-guided theta burst stimulation protocols. These are Category III codes that some practices have started billing experimentally. Under this updated policy, Aetna won't cover them for neurogenic bladder — full stop.

Coverage Indications at a Glance

Aetna Neurogenic Bladder Billing Guidelines and Action Items 2026

This policy took effect January 5, 2026. If your team hasn't already adjusted charge capture and claim workflows, do it now.

CPT, HCPCS, and ICD-10 Codes for Neurogenic Bladder Under CPB 0852

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered / Experimental CPT Codes

Not Covered / Experimental HCPCS Codes

Key ICD-10-CM Diagnosis Codes